Clinical trials
Myeloproliferative Disorders trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 4 |
| Completed | 3 |
| Recruiting | 3 |
| Terminated | 3 |
| Unknown status | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 3 |
| Incyte Corporation | 3 |
| PharmaEssentia | 2 |
| iCell Gene Therapeutics | 2 |
| Chengdu Zenitar Biomedical Technology Co., Ltd | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| Novartis Pharmaceuticals | 1 |
| Shandong University | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myeloproliferative Disorders | 17 |
| Primary Myelofibrosis | 8 |
| Myelodysplastic Syndromes | 5 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 |
| Thrombocythemia, Essential | 3 |
| Hematologic Neoplasms | 2 |
| Leukemia | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Anemia | 1 |
| Blast Crisis | 1 |
Trials
Showing 51 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.